Taken together, these results indicate that the high ACE2 expression in lung cancer might lead to a higher risk of SARS-CoV-2 entry but not a higher risk of the severity of COVID-19, and should be a safe therapy target. The gene discussed is ACE2; the disease is COVID-19.